Slated to be operational in August 2001, the new programme will combine National Jewish's intellectual property, recognised as some of the most authoritative in the industry with respect to respiratory illnesses, with PeopleMed.com's innovative Internet chronic disease management software application.
"Our Application Service Provider (ASP) will give National Jewish the most comprehensive and robust respiratory disease management software platform on the market today", stated Michael I. Ruxin, MD, Chairman and CEO of Global Med Technologies and PeopleMed.com. "Combining both strengths into one software programme will not only assist medical professionals in managing a patient's chronic disease, but will also greatly improve the quality of care for the patient, while reducing costs."
"Currently, thousands of patients in forty US states have access to our expertise. PeopleMed's Internet-based suite of products will be used to more efficiently manage our patients who suffer from asthma and COPD. The ability to reach and more effectively help our patients is very exciting", commented David Tinkelman, MD, vice president of Health Initiatives for National Jewish.
PeopleMed's disease management software products provide health care professionals immediate access to comprehensive clinical information for patients with chronic diseases. Managed care and disease management organisations use PeopleMed's products as a way to manage and monitor patients suffering from multiple chronic illnesses or co-morbidities by effectively merging treatment protocols so they can be managed as one complex disease.
PeopleMed.com Inc.'s parent, Global Med Technologies Inc., is an e-Health medical information technology company which provides information management software products and services to the health care industry. Its Wyndgate Technologies division is a supplier of management information systems to US blood centres. Current clients of Wyndgate's products and services manage more than 2,5 million units of blood or over 20 percent of the US blood supply each year.
Recognised by US News and World Report as the number one respiratory hospital in the United States for the third straight year, National Jewish is the only medical and research centre in the United States devoted entirely to respiratory, allergic, and immune system diseases, including asthma, tuberculosis, emphysema, severe allergies, AIDS, cancer, and auto-immune diseases, such as lupus. Founded in 1899 as a non-sectarian, non-profit hospital for tuberculosis patients, National Jewish enters the 21st century dedicated to enhancing prevention, treatment, and cures through research, and developing and providing innovative clinical programmes.